<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103813</url>
  </required_header>
  <id_info>
    <org_study_id>Beraprost Sodium treat STEMI</org_study_id>
    <nct_id>NCT05103813</nct_id>
  </id_info>
  <brief_title>Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI</brief_title>
  <official_title>Protective Effect of Beraprost Sodium Tablets on Coronary Microcirculation Function and Ventricular Remodeling After Reperfusion Therapy for Acute ST Segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and&#xD;
      ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial&#xD;
      infarction&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>1 weeks after baseline</time_frame>
    <description>The incidence of mace after 1 week of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>The incidence of mace after 6 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events</measure>
    <time_frame>1 year after baseline</time_frame>
    <description>The incidence of mace after 1 year of treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Beraprost Sodium Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost Sodium Tablets</intervention_name>
    <description>Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction</description>
    <arm_group_label>Beraprost Sodium Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  It meets the diagnostic criteria of acute ST segment elevation myocardial infarction:&#xD;
             ① ischemic chest pain lasts for more than 30 minutes and can not be relieved by taking&#xD;
             nitroglycerin; ② ST segment elevation of ECG with two or more adjacent leads, limb&#xD;
             lead ≥ 1mm, chest lead ≥ 2mm; Or new left bundle branch block; ③ The serum markers of&#xD;
             myocardial necrosis increased at least twice the normal value&#xD;
&#xD;
          -  Acute myocardial infarction was confirmed by coronary angiography&#xD;
&#xD;
          -  The clinical and angiographic data were complete&#xD;
&#xD;
          -  Direct PCI was performed within 12 hours after onset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who do not cooperate in the inspection, have poor compliance and cannot&#xD;
             guarantee the completion of the test&#xD;
&#xD;
          -  Conscious disorder, obvious intellectual disorder and mental disorder&#xD;
&#xD;
          -  With metal foreign bodies, such as metal prosthesis, intraocular metal foreign bodies,&#xD;
             intracranial aneurysm clamp, etc&#xD;
&#xD;
          -  People with claustrophobia&#xD;
&#xD;
          -  Had a history of myocardial infarction, PCI and coronary artery bypass grafting&#xD;
&#xD;
          -  Factors affecting ST segment changes of ECG: complete left bundle branch block,&#xD;
             preexcitation syndrome, pacemaker ECG, etc&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shenzhen People' S Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Bo He</last_name>
      <phone>13434792084</phone>
      <email>527768709@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beraprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

